Treat Asia Quality Assurance Scheme

1. Treat Asia Quality Assurance Scheme Supported by AMFAR and coordinated by the National Reference Laboratory in Australia Sally Land.

2. A Quality Assessment Scheme to Standardize the Outcome of HIV Genotypic Drug Resistance Testing in a group of Asian Laboratories Sally Land1, Philip Cunningham2, Jialun Zhou2, Kevin Frost3, David Katzenstein4, Rami Kantor5, Allison DeLong5, David Sayer6, Jeffery Smith3, Elizabeth M Dax1 and Matthew Law2 on behalf of the TAQAS Laboratory Group. 1 National Serology Reference Laboratory, Australia, Melbourne, Victoria, Australia; 2 The National Centre in HIV Epidemiology and Clinical Research, Sydney, Australia; 3 The Foundation of AIDS Research, New York, NY, USA; 4 Stanford University, Stanford, CA, USA; 5 Brown University, Providence, RI, USA; and 6Conexio Genomics, Fremantle, W.A., Australia.

7. 9 panels in 23 labs, % detection

10. 100 80 60 % Viral mixtures detected 40 20 0 TAQAS 1 TAQAS 2 TAQAS 3 TAQAS 4 Lab ID 1 – 10 Lab ID 1 – 11Lab ID 1 – 11Lab ID 1 - 16

11. Participants demonstrated high level agreement at the nucleotide sequence level that was consistent with that reported in the literature (Figure 1) (5). • Participants maintained a high level of detection of DRMs that was consistent with the level of detection achieved in other EQAS (Figure 2) (6). • Participants’ detection of viral mixtures varied and correlated with detection of DRMs (Pearson’s r: p<.05), therefore ability to detect viral mixtures reflects, to a certain degree, the quality of testing (Figure 3). • Participants’ detection of viral mixtures may be influenced by the proportion of DRMs present as mixtures of mutant and wild type virus, nucleotide sequence quality and sequence editing. • Agreement in interpretation of ARV susceptibility may be increased when all participants use the same system.